Global Press Releases
Navigate within 'Global Press Releases'
Novartis wins GBCHealth Business Action on Health Award for social ventures initiative
Basel, Switzerland, May 17, 2013
Novartis is pleased to announce that GBCHealth, a coalition of more than 230 private sector companies working to improve global health, has awarded the company's Arogya Parivar program the Business Action on Health Award for Application of Core Competence. Arogya Parivar is a sustainable business model that makes affordable, high-quality medicines accessible to underserved millions in India. The program also expands access to health education and consultations in remote villages.
New episode of Sandoz TV available
May 13, 2013
Sandoz has just launched its thirteenth episode of Sandoz TV.
Celebrating Novartis’ 17th Community Partnership Day
Holzkirchen, Germany, April 25, 2013
On April 25th we celebrate Novartis’ 17th annual Community Partnership Day. This company-wide initiative, which encourages all associates to engage in volunteering for charitable causes, is another example of our long-standing commitment to being a responsible company.
Sandoz Files for Marketing Authorization of Biosimilar Filgrastim in Japan
Tokyo, Japan, April 25, 2013
Sandoz today announced that it has filed an application with the Japanese health authority (PMDA) for marketing authorization of EP2006, a biosimilar version of recombinant human granulocyte colony stimulating factor (G-CSF).
Novartis announces Q1 2013 results
Basel, April 24, 2013
Novartis delivered solid performance in the first quarter, with eight key regulatory approvals and all divisions contributing to growth
Sandoz’ Mark McCamish ranked 12th most influential person in antibody industry
Holzkirchen, Germany, April 18, 2013
The European Antibody Congress 2013 has named Sandoz’ Mark McCamish, Head Global Biopharmaceutical Development, as one of the top 50 global antibody industry influencers of today.
Sandoz strengthens oral contraceptive portfolio by launching generic versions of Ortho Cyclen® and Ortho Tri-Cyclen®
Princeton, New Jersey, March 19, 2013
Sandoz today announced the US Food and Drug
Administration (FDA) approvals and US launches of Estarylla™ (norgestimate and ethinyl estradiol
tablets) and Tri-Estarylla™ (norgestimate and ethinyl estradiol tablets), generic equivalents of the oral
contraceptives Ortho Cyclen® and Ortho Tri-Cyclen®.
Sandoz expands Kundl site sterile production
Kundl, Austria, March 11, 2013
Sandoz officially opened its new facilities in Kundl, Austria, thereby expanding the production of sterile penicillins at the site significantly and creating 30 new jobs.
Sandoz launches an authorized generic version of argatroban injection (aqueous solution for intravenous infusion)
Princeton, New Jersey, February 19, 2013, February 19, 2013
Sandoz today announced the US launch of an authorized generic version of Eagle Pharmaceuticals’ ready-to-use argatroban injection 50 mg/50mL, aqueous solution (1 mg/mL).
Sandoz launches first generic version of Cleocin Phosphate® in Dextrose 5%
Princeton, New Jersey, February 06, 2013
Sandoz today announced the US Food and Drug
Administration (FDA) approval and US launch of clindamycin in 5% dextrose in minibag form, the first
generic version of Cleocin Phosphate® in Dextrose 5%.
